

***In vitro* impact of human milk oligosaccharides on *Enterobacteriaceae* growth**

Jennifer L. Hoeflinger¹, Steven R. Davis², JoMay Chow², Michael J. Miller^{1*}

¹Department of Food Science and Human Nutrition, University of Illinois Urbana
Champaign, 905 S Goodwin Ave Urbana, IL 61801 and ²Abbott Nutrition, 3300 Stelzer Rd
Columbus, OH 43219

***Correspondence:** Michael J. Miller, Telephone: (217) 244-1973; Fax: (217) 265-0925;

E-mail: mille216@illinois.edu

Supplemental Figure Legends

Figure S1. Lag time, hr, achieved on 1 % fermentable substrate (Glucose, Lactose or Maltodextrin) or 1 % fermentable substrate supplemented with 1 % HMO (2'-Fucosyllactose [2'-FL], 6'-Sialyllactose [6'-SL], Lacto-N-neotetraose [LNnT]) in ZMB-1 media. Blank corrected by subtraction of wells containing no cells and no carbohydrate. Statistical significance determined by ANOVA using Dunnett's test; * $p < 0.1$, ** $p < 0.05$, *** $p < 0.005$. Average of 3 or more independent experiments.

Figure S2. Doubling time, hr, achieved on 1 % fermentable substrate (Glucose, Lactose or Maltodextrin) or 1 % fermentable substrate supplemented with 1 % HMO (2'-Fucosyllactose [2'-FL], 6'-Sialyllactose [6'-SL], Lacto-N-neotetraose [LNnT]) in ZMB-1 media. Blank corrected by subtraction of wells containing no cells and no carbohydrate. Statistical significance determined by ANOVA using Dunnett's test; * $p < 0.1$, ** $p < 0.05$, *** $p < 0.005$. Average of 3 or more independent experiments.

Figure S3. Max deltaOD, 600nm, achieved on 1 % fermentable substrate (Glucose, Lactose or Maltodextrin) or 1 % fermentable substrate supplemented with 1 % HMO (2'-Fucosyllactose [2'-FL], 6'-Sialyllactose [6'-SL], Lacto-N-neotetraose [LNnT]) in ZMB-1 media. Blank corrected by subtraction of wells containing no cells and no carbohydrate. Statistical significance determined by ANOVA using Dunnett's test; * $p < 0.1$, ** $p < 0.05$, *** $p < 0.005$. Average of 3 or more independent experiments.

Supplemental Figures




Figure S1. Impact of purified HMO supplementation on the lag time of *in vitro* utilization of a fermentable substrate by selected *Enterobacteriaceae*.






Figure S2. Impact of purified HMO supplementation on the doubling time of *in vitro* utilization of a fermentable substrate by selected *Enterobacteriaceae*.






Figure S3. Impact of purified HMO supplementation on the delta OD of *in vitro* utilization of a fermentable substrate by selected *Enterobacteriaceae*.

